Health Bulletin 5/June/2023

Here are the top health stories for the day:

Death of pregnant woman, unborn child: NCDRC holds Bengaluru hospital, anesthetist guilty of medical negligence, orders Rs 1.6 crore compensation

The National Consumer Disputes Redressal Commission (NCDRC) has directed a Bengaluru-based hospital and its Anesthetist to pay altogether Rs 1.6 crore compensation to the family members of a patient, who died while undergoing Caesarean Section along with her unborn baby.

While the hospital and the treating doctors claimed that the death of the patient happened due to anaphylactic reaction, the top consumer court disagreed with this opinion. Relying upon the Post Mortem findings and expert opinions, the NCDRC bench observed that the patient died due to hemorrhagic shock which could be only due to trauma inside the OT.

For more details, check out the link given below:

Death of Pregnant Woman, Unborn Child: NCDRC holds Bengaluru Hospital, Anesthetist Guilty of Medical Negligence, Orders Rs 1.6 crore compensation

NMC approves 100 MBBS seats for DRIEMS Institute of Health Sciences and Hospital

Bringing good news to medical aspirants in Odisha, the National Medical Commission (NMC) has approved the proposal for starting a new medical college at DRIEMS Institute of Health Sciences and Hospital, Cuttack under Utkal University, Bhubaneswar.

The apex medical education regulatory body NMC has permitted the state to commence the MBBS admission in 100 seats at the medical college from the academic year 2023-2024. The proposal has been approved based on the assessment reports and compliance verification assessments. 

For more details, check out the link given below:

NMC approves 100 MBBS seats for DRIEMS Institute of Health Sciences and Hospital

Need well-designed protocol with statistically validated sample size: CDSCO panel tells Dr Reddy's on Nerivio

In line with the proposal to conduct a pivotal clinical investigation of the proposed product Nerivio, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the pharmaceutical giant Dr. Reddy's laboratories that the study should be under a scientifically robust, well-designed protocol with a statistically validated sample size.

In regards to the above, the expert panel suggested the firm submit a revised protocol for further review by the committee.

For more details, check out the link given below:

Need well-designed protocol with statistically validated sample size: CDSCO Panel Tells Dr. Reddy's on Nerivio